Author

C. Redfern

Observed names: C Redfern, Cameron Redfern, Cameron T Redfern

Institution: Harry Perkins Institute of Medical Research

Observed institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Louisville, The University of Western Australia, Harry Perkins Institute of Medical Research, Dana-Farber Cancer Institute, Aichi Cancer Center, The Cancer Institute Hospital, National Cancer Center Hospital East, Japanese Foundation For Cancer Research, National Cancer Center Hospital, Kindai University

OpenAlex ID: A5108474178

Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study

2019 · S Modi, J Tsurutani, et al. · Cancer Research · 27

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity

2025 · Bo He, Kira H Wood, et al. · EMBO Molecular Medicine · 17

275 Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 4-fluorouracil-containing regimen

2003 · C. Redfern, J. Schulz, et al. · European Journal of Cancer Supplements · 5

Exploring Traditional Breast Cancer Risk Genes Among Aboriginal and Torres Strait Islander Women

2026 · Katie Meehan, Leanne Pilkington, et al. · Life

59P The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer

2020 · A. Khan, T. Dale, et al. · Annals of Oncology

Works count: 5

Citation count: 49

H-index: 3

I10-index: 2